As language models (LMs) improve at tasks like image generation, trivia questions, and simple math, you might think that ...

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech on track to start a pivotal study next year. The Californian company’s ...

Neural encoding is the study of how neurons represent information with electrical activity (action potentials) at the level of individual cells or in networks of neurons. Studies of neural encoding ...